HTB South http://i-base.info/htb-south HIV treatment research reports for southern Africa Sat, 17 Mar 2012 12:22:32 +0000 http://backend.userland.com/rss092 en Volume 5 Number 1 January/March 2012 http://i-base.info/htb-south/1734/ 2nd International Workshop on HIV & Women, 9-10 January 2012, Bethesda, USA http://i-base.info/htb-south/1730/ Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks http://i-base.info/htb-south/1728/ The effect of BMI on efficacy, safety and tolerability of lopinavir/r in women http://i-base.info/htb-south/1726/ Hormonal contraception and higher risk of non-AIDS-defining events in Nashville cohort http://i-base.info/htb-south/1724/ Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes http://i-base.info/htb-south/1722/ 5th HIV Persistence Workshop on HIV Reservoirs, 6-9 December 2011, West Indies http://i-base.info/htb-south/1719/ Workshop report and commentary http://i-base.info/htb-south/1717/ 13th European AIDS Conference (EACS), Belgrade, Serbia, 12–15 October 2011 http://i-base.info/htb-south/1713/ Raltegravir achieves superiority over efavirenz after four years http://i-base.info/htb-south/1711/ Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients http://i-base.info/htb-south/1709/ Ritonavir levels reduced with high fat meal http://i-base.info/htb-south/1707/ Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates http://i-base.info/htb-south/1705/ 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, 17–20 September 2011 http://i-base.info/htb-south/1703/ Monitoring kidney function change with cobicistat http://i-base.info/htb-south/1701/ Intracellular raltegravir concentrations better with twice-daily than once-daily dosing http://i-base.info/htb-south/1699/ Tenofovir label extended to paediatric indication http://i-base.info/htb-south/1686/ FDA approve US paediatric dose for raltegravir http://i-base.info/htb-south/1693/ FDA approve paediatric dose for darunavir http://i-base.info/htb-south/1689/ Efavirenz dose increase to 800 mg QD with rifampin in patients >50 kg http://i-base.info/htb-south/1691/ FDA updates US label for darunavir for serious rash http://i-base.info/htb-south/1684/ FDA updates US label for raltegravir due to serious rash http://i-base.info/htb-south/1682/ Lopinavir concentrations suboptimal at reduced dose of lopinavir/ritonavir 200/50 mg twice daily http://i-base.info/htb-south/1679/ Switching to 50mg ritonavir dose for selected protease inhibitors http://i-base.info/htb-south/1677/ New formulations, acquisitions and company announcements http://i-base.info/htb-south/1675/ BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011 http://i-base.info/htb-south/1671/ Draft BHIVA ARV treatment guidelines online for comment until 5 March http://i-base.info/htb-south/1669/ Draft BHIVA pregnancy guidelines online for comment until 5 March http://i-base.info/htb-south/1667/ US guidelines (DHHS) update recommendations for first-line combinations (October 2011) http://i-base.info/htb-south/1664/ FDA approval of generic ARVs http://i-base.info/htb-south/1661/ Disastrous warning for global HIV programmes in 2012 http://i-base.info/htb-south/1659/ Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager http://i-base.info/htb-south/1656/ Janssen block Patent Pool access to darunavir, rilpivirine and etravrine http://i-base.info/htb-south/1654/ UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria http://i-base.info/htb-south/1652/ We need the Patent Pool to work http://i-base.info/htb-south/1650/ Call to Action on Global Fund restriction to new funding to 2014 http://i-base.info/htb-south/1648/ Analysis of why the Global Fund cancelled Round 11 http://i-base.info/htb-south/1646/ Reaction to the Global Fund’s decisions on Round 11 and grant renewals http://i-base.info/htb-south/1644/ Delaying ART in childhood can reduce long-term CD4 count in adulthood http://i-base.info/htb-south/1641/ Efavirenz under-dosing in children http://i-base.info/htb-south/1639/ Treatment response and duration of first line treatment in European infants http://i-base.info/htb-south/1637/ No increased risk of non-AIDS deaths from cumulative use of ART in EuroSIDA cohort http://i-base.info/htb-south/1634/ Need for expanded access to two promising MDR TB drugs http://i-base.info/htb-south/1631/ ZAMSTAR study suggests active case finding in households reduces TB prevalence http://i-base.info/htb-south/1629/ A court case and a model show how poor conditions are fueling a TB epidemic in prisons http://i-base.info/htb-south/1627/ Interactions between nevirapine and antimalarials (artemether and lumefantrine) http://i-base.info/htb-south/1624/ Interactions between antiretrovirals and complementary and African traditional medicines http://i-base.info/htb-south/1622/ Drug interactions between sirolimus (rapamycin) and ARVs http://i-base.info/htb-south/1620/ International PrEP study (VOICE) discontinues use of tenofovir vaginal gel due to lack of efficacy http://i-base.info/htb-south/1617/ Infant feeding: TAC’s position http://i-base.info/htb-south/1614/ WHO upholds guidance on hormonal contraceptive use and HIV http://i-base.info/htb-south/1612/ New York court rejects AIDS denialist case against leading HIV community activist and journalist http://i-base.info/htb-south/1609/ Volume 5 Number 1 January/March 2012 PDF http://i-base.info/htb-south/1738/ 2012 conference listing http://i-base.info/htb-south/921/ Volume 4 Number 4 October/December 2011 http://i-base.info/htb-south/1799/ 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17–20 July 2011, Rome http://i-base.info/htb-south/1796/ Cure research and viral reservoirs http://i-base.info/htb-south/1789/ Orange Farm circumcision results dispel concerns about risk compensation http://i-base.info/htb-south/1787/ Randomised trial of ART in TB patients with high CD4 counts http://i-base.info/htb-south/1785/ FDA approval of generic ARVs http://i-base.info/htb-south/1783/ Increased risk of preterm delivery with protease inhibitor based HAART in Mma Bana http://i-base.info/htb-south/1779/ Efavirenz in pregnancy: update of systemic review and meta-analysis http://i-base.info/htb-south/1777/ AZT not equivalent to HAART to prevent mother-to-child transmission in a Botswana programme http://i-base.info/htb-south/1775/ Increased risk of HIV transmission to HIV-negative partners during pregnancy http://i-base.info/htb-south/1764/ Pharmacokinetics of paediatric tenofovir based regimens http://i-base.info/htb-south/1761/ Atazanavir pharmacokinetics in infants, children and adolescents http://i-base.info/htb-south/1759/ Crushing lopinavir/ritonavir tablets decreases exposure by almost half in children http://i-base.info/htb-south/1757/ WHO Guidelines on guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update http://i-base.info/htb-south/1755/ IPT for adults: Should the Mantoux test have been removed from WHO guidelines? http://i-base.info/htb-south/1752/ DSMB stops oral tenofovir monotherapy arm of VOICE PrEP study due to lack of difference compared to placebo http://i-base.info/htb-south/1750/ Volume 4 Number 4 October/December 2011 PDF http://i-base.info/htb-south/1743/ HTB SUPPLEMENT: 2011 pipeline report http://i-base.info/htb-south/1594/ Volume 4 Number 3 July/September 2011 http://i-base.info/htb-south/1597/ 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17–20 July 2011, Rome http://i-base.info/htb-south/1547/ Webcasts for major research at IAS http://i-base.info/htb-south/1545/ Treatment is prevention: ARV treatment in HPTN-052 reduces transmission by at least 96%: single transmission in treatment arm occurred prior to viral suppression http://i-base.info/htb-south/1542/ Daily oral tenofovir/FTC PrEP reduces heterosexual transmission by 63% in the TDF2 study http://i-base.info/htb-south/1539/ Tenofovir/FTC vs tenofovir as daily oral PrEP: preliminary results from Partners PrEP http://i-base.info/htb-south/1536/ Elvitegravir vs raltegravir: 48 week results in treatment-experienced patients http://i-base.info/htb-south/1534/ Dolutegravir: 48 week results from phase II study in treatment-naïve patients http://i-base.info/htb-south/1532/ Lersivirine: 48 week results compared to efavirenz in phase 2 treatment-naïve study http://i-base.info/htb-south/1530/ SPARTAC trial: treatment in primary infection for 48 weeks shows small delay in disease progression http://i-base.info/htb-south/1528/ Hearing loss not associated with HIV in MACS and WIHS cohorts http://i-base.info/htb-south/1526/ Pharmacokinetics of darunavir and fosamprenavir in pregnancy http://i-base.info/htb-south/1523/ Low birth weight and preterm delivery http://i-base.info/htb-south/1521/ Hormonal contraception and HIV transmission risk http://i-base.info/htb-south/1519/ No difference in AIDS-free survival in children starting ART with a CD4% between 15%–24% compared to deferring until less than 15% in the PREDICT trial http://i-base.info/htb-south/1517/ Paediatric antiretroviral pipeline: update on etravirine and maraviroc http://i-base.info/htb-south/1515/ More metabolic abnormalities in children receiving a PI compared to NNRTI in NEVEREST study http://i-base.info/htb-south/1513/ Prematurity not associated with early mortality in infants on ART http://i-base.info/htb-south/1511/ Free online resource for treatment decisions without access to genotype resistance tests http://i-base.info/htb-south/1509/ 18th Conference on Retroviruses and Opportunistic Infections (CROI) 27 February–3 March 2011, Boston http://i-base.info/htb-south/1505/ Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials http://i-base.info/htb-south/1504/ DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching http://i-base.info/htb-south/1502/ Lopinavir/r monotherapy used as second-line therapy in resource-limited settings http://i-base.info/htb-south/1499/ Pharmacokinetics of different rifabutin dosing strategies with lopinavir/ritonavir-based ART http://i-base.info/htb-south/1496/ Initiation of ART during breastfeeding can induce multidrug resistance in infants http://i-base.info/htb-south/1494/ Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST http://i-base.info/htb-south/1492/ Lopinavir/ritonavir oral solution toxicity in neonates http://i-base.info/htb-south/1485/ Paediatric antiretroviral pipeline: darunavir and raltegravir http://i-base.info/htb-south/1487/